GM0N Stock Chart & Stats
€71.06
€1.32(1.95%)
At close: 4:00 PM EDT
€71.06
€1.32(1.95%)
Day’s Range― - ―
52-Week Range€51.50 - €83.50
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
€9.74B
Enterprise Value€10.37B
Total Cash (Recent Filing)€595.14M
Total Debt (Recent Filing)€111.19M
Price to Earnings (P/E)20.5
Beta0.34
Next Earnings
Nov 05, 2026EPS Estimate
1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.97
Shares Outstanding111,831,820
10 Day Avg. Volume0
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.58
Price to Sales (P/S)4.02
P/FCF Ratio20.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€87.92Price Target Upside23.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)4.45
Revenue Forecast (FY)€2.85B
Bulls Say, Bears Say
Bulls Say
Spine GrowthBroad growth across U.S. and international spine markets indicates durable procedural demand and continued commercial traction. Expansion across multiple geographies can strengthen market position and provide a foundation for sustained revenue growth over the next several quarters.
Cash Generation And Balance SheetVery low leverage and strong operating cash generation provide financial flexibility to fund product development, commercial investment, and integration work internally. This reduces balance-sheet pressure while supporting continued investment in the company’s growth opportunities.
Product And Robotic AdoptionGrowing utilization of Excelsius technology and higher system deployments support the company’s enabling-technology platform and surgical workflow ecosystem. Increased adoption can create recurring procedure-related demand and reinforce differentiation in spine and adjacent musculoskeletal care.
Bears Say
Enabling Technology Revenue PressureThe shift toward flexible capital models is reducing near-term cash sales and reported enabling-technology revenue even as deployments grow. This transition can delay revenue recognition, complicate forecasting, and pressure near-term growth until related implant pull-through develops.
Nevro Integration DragNevro’s declining sales and ongoing integration changes are creating a meaningful drag on consolidated growth. Until product development, sales execution, and trial volumes stabilize, the acquisition may require management attention and weigh on revenue progression and operating consistency.
Margin VolatilityAlthough current profitability is healthy, the decline in gross margin versus 2025 and inconsistent historical results indicate that earnings power remains sensitive to mix, pricing, or cost pressures. Persistent volatility could limit the durability of margin expansion and earnings growth.
GM0N FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was €51.50 and its highest was €83.50 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is €9.74B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is Nov 05, 2026 which is in 10 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Aug 06, 2026. The company reported €1.194 earnings per share for the quarter, beating the consensus estimate of €0.979 by €0.215.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 1.07.
How many shares outstanding does Globus Medical have?
Globus Medical has 111,831,820 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of €1.194 in its last earnings report, beating expectations of €0.979. Following the earnings report the stock price went up 1.558%.
Which hedge fund is a major shareholder of Globus Medical?
Currently, no hedge funds are holding shares in DE:GM0N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Globus Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€87.92 (23.73% Upside)
€87.92 (23.73% Upside)
Blogger Sentiment
Bullish
DE:GM0N Sentiment 83%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth €3.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.63%
12-Months-Change
Fundamentals
Return on Equity
11.59%
Trailing 12-Months
Asset Growth
10.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Globus Medical
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
GM0N Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive: the company reported broad-based revenue growth (including strong U.S. and International Spine), meaningful margin expansion, record non-GAAP EPS, strong cash generation and continued product and commercial momentum. The main near-term headwinds are Enabling Technologies revenue compression due to a strategic shift to flexible capital models and a temporary top-line drag from the Nevro integration and trial cadence. Management provided reaffirmed revenue guidance and raised EPS guidance, signaling confidence in margin leverage and recovery of transitional businesses.View all DE:GM0N earnings summariesGM0N Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies

GM0N Stock 12 Month Forecast
Average Price Target
€87.92
▲(23.73% Upside)











